In addition, SIRT1 has been shown to facilitate pancreatic cancer chemoresistance, while application of a combination therapy consisting of a SIRT1 inhibitor and gemcitabine has been shown to have enhanced efficacy for pancreatic cancer [53, 54]. This evidence concerns the gene SIRT1 and familial pancreatic carcinoma.